spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Avastin 

 HSMN NewsFeed - 12 Jul 2021
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Mar 2021
PACT Pharma Announces Planned Retirement of CEO Alex Franzusoff; Veteran Biotech Executive Scott Garland Named as Successor
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Jun 2020
Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 28 May 2020
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Mar 2020
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Aug 2019
Erasca Announces Key Leadership Team Appointments and Recruits World-Class Research and Development Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Apr 2019
DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Aug 2018
IGM Biosciences Appoints Julie Hambleton, M.D., to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Jun 2018
DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 May 2018
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
Biopharmaceuticals Generics Licensing
 HSMN NewsFeed - 12 Feb 2018
ImmunoMet Appoints Vincent J. O'Neill, M.D., B.Sc., M.R.C.P, as Chief Medical Officer, and Allan L. Shaw as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Nov 2017
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Jun 2017
DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jan 2017
Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Jan 2016
Immunotherapy Company PDS Biotechnology Strengthens Senior Management Team, Adds Two Drug Development Executives
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Jan 2016
CytRx Corporation Appoints Olivia Ware as Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Nov 2015
Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Sep 2015
Cerulean Appoints David R. Walt, Ph.D. to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Mar 2015
VBL Therapeutics Reports Interim Topline Results From Phase 2 Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Mar 2015
Sirtex Reports Preliminary SIRFLOX Study Results
Devices Drug Delivery Oncology
 HSMN NewsFeed - 29 Jan 2015
Cerulean Appoints Vice President, Clinical Operations
Biopharmaceuticals Drug Delivery Oncology Personnel
 HSMN NewsFeed - 6 Jan 2015
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Oct 2014
EYLEA(R) (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 14 Aug 2014
FDA Approves Genentech’s Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Jul 2014
FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Jul 2014
FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Apr 2014
Epirus and Zalicus Announce Merger Agreement
Biopharmaceuticals Mergers & Acquisitions Venture Capital
 HSMN NewsFeed - 25 Mar 2014
Tocagen Names Jamey Skillings, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Feb 2014
PDL BioPharma Announces Agreement with Genentech and Roche to Settle Litigation and Arbitration
Biopharmaceuticals Litigation
 HSMN NewsFeed - 27 Jan 2014
Biothera Names VP of Biomarker Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Nov 2013
Threshold Pharmaceuticals Announces New Clinical Data on TH-302 and Avastin(R) (Bevacizumab) in Recurrent Glioblastoma Following Bevacizumab Failure
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Aug 2013
bioTheranostics Appoints Three Key Executives
Diagnostics Personalized Medicine Oncology Personnel
 HSMN NewsFeed - 18 Jun 2013
John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Apr 2013
BIND Therapeutics Appoints Gregory I. Berk, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jan 2013
Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jan 2013
Tau Therapeutics Hires Chief Medical Officer and VP of Operations and Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Nov 2012
John A. Orwin Joins Array BioPharma Board Of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Aug 2012
Genentech Study Showed That Adding Avastin to Radiation and Chemotherapy Significantly Extended the Time People with an Aggressive Form of Brain Cancer Lived without Their Disease Worsening
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2012
Epizyme Announces Appointment of Eric Hedrick, M.D., as Chief Medical Officer
Biopharmaceuticals Personalized Medicine Personnel
 HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Oct 2011
Exelixis Appoints Executive Vice President and Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Sep 2011
DelMar Pharmaceuticals Receives FDA IND Approval to Begin Clinical Trials With A New Brain Cancer Treatment
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Jun 2011
Sheila Gujrathi, M.D. Named Chief Medical Officer of Receptos
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jun 2011
Marshall Edwards Adds Former Genentech Head of Medical Affairs Robert Mass as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Apr 2011
Arno Therapeutics Announces the Appointment of Mr. Glenn Mattes as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Feb 2011
FDA Grants Genentech a Hearing on Avastin’s Use for Metastatic Breast Cancer in the United States
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Feb 2011
Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Dec 2010
Genentech Provides Update on Avastin for Metastatic Breast Cancer Following Reviews in Europe and the United States
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Nov 2010
Seattle Genetics Announces Additions to Commercial Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Nov 2010
VeriStrat(R) Test Identifies Lung Cancer Patients Benefiting from Combination Therapy
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 24 May 2010
Seattle Genetics Names Vice President, Sales and Announces Management Promotion
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Apr 2010
Affymax Names John A. Orwin President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Apr 2010
Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Apr 2010
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Mar 2010
Genentech Provides Update on Phase III Study of Avastin in Men With Late Stage Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Feb 2010
Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Feb 2010
Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Nov 2009
NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Nov 2009
Genentech Submits Supplemental Applications to FDA for Avastin Combined with Commonly Used Chemotherapies for Women with Advanced Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Oct 2009
Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Sep 2009
Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Aug 2009
Sutro Biopharma Announces Additions to Board of Directors and Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Aug 2009
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Aug 2009
FDA Approves Avastin for the Most Common Type of Kidney Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 May 2009
FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Apr 2009
Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Feb 2009
Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jan 2009
New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Nov 2008
Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival In Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2008
Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2008
Genentech Announces Phase III Study of Avastin Plus Chemotherapy in Adjuvant Colon Cancer Will Continue
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Sep 2008
New Data Confirms Avastin (R) as the Only Biologic to Demonstrate Overall Survival When Used First-Line in Metastatic Colorectal Cancer Patients With K-RAS (Wild-Type) Gene Status
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Aug 2008
Monoclonal Antibody Sales to Almost Double in Coming Years
Biopharmaceuticals
 HSMN NewsFeed - 2 Aug 2008
Lung Cancer Epidemic Looming in Asia?
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2008
Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jun 2008
Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2008
New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
Study Confirms That Avastin Significantly Increases Chance of Living Without Disease Progression in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
Patients With Pancreatic Cancer can Benefit From Avastin(R) Plus Tarceva(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
Data Confirm Avastin(R) Helps Patients With Metastatic Colorectal Cancer Live Even Longer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 May 2008
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Apr 2008
Genentech Provides Update on ''AVAiL'' Phase III Study of Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2008
FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S.
Devices Ophthalmology FDA
 HSMN NewsFeed - 28 Mar 2008
NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
Devices Ophthalmology
 HSMN NewsFeed - 28 Mar 2008
Positive results from Visudyne(R) combination therapy study reported at Annual Macula Society Conference
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 24 Mar 2008
Pro-Pharmaceuticals Announces DAVANAT(R) Regimen Approved to Treat Breast Cancer Patient
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Mar 2008
Genentech Provides Business Update at Annual Investment Community Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Mar 2008
Pro-Pharmaceuticals DAVANAT(R) Extends Median Survival 6.7 Months for End-Stage Colorectal Cancer Patients After All Other Treatments Failed
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Feb 2008
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2008
FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Feb 2008
New Data Shows DAVANAT(R) Extends Survival of End-Stage Colorectal Cancer Patients More Than 6 Months
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Dec 2007
Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Dec 2007
Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Dec 2007
Genentech Provides Update from Avastin FDA Advisory Meeting
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Nov 2007
Avastin Shows Encouraging Results in Phase II Study in Patients With the Most Aggressive Form of Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Sep 2007
BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Sep 2007
Pro-Pharmaceuticals Names Theodore Zucconi, Ph.D., President; Nominated to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Sep 2007
Roche's Tarceva(R) Delivers Longer Life for Lung Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Aug 2007
Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Aug 2007
ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Aug 2007
NCCN Updates Kidney Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jul 2007
Pro-Pharmaceuticals Updates Progress of Clinical Trials & DAVANAT(R) 505 (b)(2) Filings
Biopharmaceuticals Oncology Drug Delivery
 HSMN NewsFeed - 5 Jun 2007
OSI Pharmaceuticals Summarizes Data on Tarceva(R) (erlotinib) at the 2007 American Society of Clinical Oncology (ASCO) Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Genentech Provides Update on Pipeline Agents at the American Society of Clinical Oncology Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Xeloda(R) Plus Avastin(R) Combination Delays Disease Progression in Women with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Phase III Study Shows Avastin Plus Interferon Therapy Nearly Doubled Median Progression-Free Survival in Patients With Previously Untreated Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2007
SuperGen Names Gregory Berk, M.D., Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 May 2007
Poniard Pharmaceuticals Appoints Ronald A. Martell President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Apr 2007
Pro-Pharmaceuticals Issues Corporate Update
Biopharmaceuticals
 HSMN NewsFeed - 16 Apr 2007
Data Presented at AACR Meeting Shows Peregrine's Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Apr 2007
Pro-Pharmaceuticals Plans to Submit a New Drug Application for DAVANAT(R), as a Functional Excipient, with 5-FU to Treat Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2007
Pro-Pharmaceuticals Receives Letter from the FDA for New Drug Application for DAVANAT(R)/ 5-FU
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Apr 2007
Trellis Bioscience Names Bruce Keyt, Ph.D. as Chief Technology Officer and Vice President of Research
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Apr 2007
Pro-Pharmaceuticals Announces Tampa General Hospital Dosing Patients with DAVANAT(R)/5-FU in Phase II, First Line, Advanced Biliary Cancer Clinical Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Apr 2007
Roche Acquires THP in $56.5 Million Deal
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Mar 2007
Nuvelo Receives FDA Fast Track Status for rNAPc2 in Both First- and Second-Line Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Mar 2007
Roche Submits Application to the FDA for use of XELOX (Xeloda(R) plus oxaliplatin) With or Without Avastin(R) for the Treatment of Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Mar 2007
Amgen Discontinues Vectibix(TM) Treatment in Pacce Trial Evaluating Vectibix(Tm) as Part of Triple Combination Regimen
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Feb 2007
Pro-Pharmaceuticals Submits Orphan Drug Status Application to European Medicines Agency Co-administration of DAVANAT(R) with 5-FU to Treat Cholangiocarcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Feb 2007
Pro-Pharmaceuticals Meeting Scheduled with the FDA
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2007
Analysis of International Phase III Study of Avastin(R) Plus Chemotherapy Shows Improved Progression-Free Survival in Patients With Advanced Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Feb 2007
Pro-Pharmaceuticals' Begins Process of New Drug Application Submission with the FDA for Co-administration of DAVANAT(R) with 5-FU in Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jan 2007
Introgen Reports that INGN 241 in Combination with Avastin(R) Results in Complete Tumor Regression
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jan 2007
Results Show XELOX (Xeloda(R) plus oxaliplatin) Provides Equivalent Overall Patient Survival Compared to FOLFOX in Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Jan 2007
Genentech Announces Senior Vice President and Vice President Promotions in Commercial, Legal and Product Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Dec 2006
Xeloda(R) Plus Avastin(R) Combination May Produce Clinical Benefit in Patients with Advanced Breast Cancer
Biopharmaceuticaals Oncology
 HSMN NewsFeed - 13 Dec 2006
New England Journal of Medicine Publishes Data from Pivotal Study of Avastin Plus Chemotherapy in Most Common Type of Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2006
Interim Analysis of Phase III Trial Shows Avastin Plus Interferon Therapy Improved Progression-Free Survival in Patients With Previously Untreated Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Abraxis BioScience to Present Data from Six Studies at San Antonio Breast Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Nov 2006
Adnexus Therapeutics Appoints Bruce A. Silver, MD, FACP as Medical Director
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Nov 2006
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Nov 2006
Genentech Announces Manufacturing Agreements with Lonza
Biopharmaceuticals
 HSMN NewsFeed - 16 Oct 2006
Genaera Presents New EVIZON(TM) Safety Data at the Angiogenesis Foundation 4th Annual International Conference
Biopharmacetuicals Ophthalmology
 HSMN NewsFeed - 11 Oct 2006
FDA Approves Avastin(R) in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Oct 2006
XELOX (Xeloda(R) + oxaliplatin) Shown to be as Effective as Current Standard in the Treatment of Advanced Colorectal Cancer for Progression-Free Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Sep 2006
Former Chiron Exec Joins APT Pharmaceuticals as CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Sep 2006
Roche Requests Re-Examination of CHMP Opinion on Tarceva in Pancreatic Cancer at the European Medicines Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Jul 2006
Large International Phase III Trial in Metastatic Colorectal Cancer Meets Primary Endpoints for XELOX (Xeloda(R) + Oxaliplatin) and for Avastin
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jun 2006
OXiGENE'S Board of Directors Names Experienced Biotech Executive, Richard Chin, M.D., as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jun 2006
ADVENTRX Initiates CoFactor Phase III Clinical Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jun 2006
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jun 2006
FDA Approves Avastin(R) in Combination With Chemotherapy for Second-Line Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jun 2006
Results From a Randomized Phase II Trial Suggested the Combinations of Avastin(R) Plus Tarceva(R) and Avastin Plus Chemotherapy Improved Progression- Free Survival in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2006
ADVENTRX Announces Positive CoFactor Phase II Clinical Trial Results at ASCO Conference
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2006
Updated Analysis in Second-Line Treatment of Lung Cancer Trial Confirms Similar Survival for Alimta(R) and Docetaxel
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 May 2006
Genentech Submits Supplemental Biologics License Application for Avastin With Chemotherapy in First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 May 2006
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 May 2006
Recruitment Planned to Resume in AVANT International Phase III Trial in Adjuvant Colon Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2006
ADVENTRX Receives FDA Clearance Under a Special Protocol Assessment to Initiate CoFactor Phase III Clinical Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2006
EntreMed Initiates Combination Phase 2 Clinical Trial With Panzem(R) NCD in Carcinoid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 May 2006
Genentech Announces Vice President Appointments in Commercial Operations and Product Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 May 2006
OSI Pharmaceuticals Summarizes Macugen(R) (pegaptanib sodium injection) Data Presented at Association for Research in Vision and Ophthalmology (ARVO) Meeting
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 18 Apr 2006
Lpath Introduces Ocular Division
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 11 Apr 2006
Genentech Submits Supplemental Biologics License Application for Avastin(R) With Chemotherapy in First-Line, Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Apr 2006
Genentech Announces Vice President Appointments in Commercial Operations and Product Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Apr 2006
Pro-Pharmaceuticals Reports Preliminary Data Shows an Objective Partial Tumor Response in Phase II Colorectal Cancer Trial Evaluating DAVANAT(R) with 5-FU
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Apr 2006
CancerVax Announces FDA Approval of IND for Novel Anti-Angiogenic Antibody D93
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Mar 2006
Pro-Pharmaceuticals Completes Patient Enrollment in Stage 1 of Phase II Colorectal Cancer Trial Evaluating DAVANAT(R) with 5-FU
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Mar 2006
Nereus Pharmaceuticals Closes Second Tranche of $42.6 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 15 Feb 2006
Genentech Submits Supplemental Biologics License Application for Adjuvant Herceptin(R) in Early-Stage HER2-Positive Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Feb 2006
Recruitment Temporarily Suspended in an International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Feb 2006
Pro-Pharmaceuticals Receives 'Compassionate Use' IND for Use of DAVANAT(R)/5-FU to Treat Another Patient with Cholangiocarcinoma
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 100

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 100 additional stories matching:
Avastin
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.